{ "items": [ "\n\n
Huygens S. et al, (2022), Value Health
\n \n \n \n\n \n
\n \n \nBuchanan J. et al, (2022), Journal of community genetics, 13, 463 - 466
\n \n \n \n\n \n
\n \n \nMartin L. et al, (2022), Lancet Infectious Diseases
\n \n \n \n\n \n
\n \n \nTsiachristas A. et al, (2022), BMC Cancer, 22
\n \n \n \n\n \n
\n \n \nDixon P. et al, (2022), Genetics in Medicine
\n \n \n \n\n \n
\n \n \nDixon P. et al, (2022), Genetics in Medicine
\n \n \n \n\n \n
\n \n \nBenger JR. et al, (2022), Health Technol Assess, 26, 1 - 158
\n \n \n \n\n \n
\n \n \nVellekoop H. et al, (2022), Value in Health
\n \n \n \n\n \n
\n \n \nKoleva-Kolarova R. et al, (2022), Applied Health Economics and Health Policy
\n \n \n \n\n \n
\n \n \nPollard S. et al, (2022), Value Health
\n \n \n \n\n \n
\n \n \nLim E. et al, (2022), NEJM Evidence, 1
\n \n \n \n\n \n
\n \n \nYang M. et al, (2022), Health Economics
\n \n \n \n\n \n
\n \n \nLaw CK. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40
\n \n \n \n\n \n
\n \n \nVellekoop H. et al, (2022), VALUE IN HEALTH, 25, S75 - S75
\n \n \n \n\n \n
\n \n \nBuckell J. et al, (2021), Health Econ
\n \n \n \n\n \n
\n \n \nTAYLOR J., (2021), New England Journal of Medicine
\n \n \n \n\n \n
\n \n \nBOREK A. et al, (2021), Implementation Science Communications
\n \n \n \n\n \n
\n \n \nMORRELL E., (2021), PLoS Medicine
\n \n \n \n\n \n
\n \n \nMORRELL E. et al, (2021), PharmacoEconomics
\n \n \n \n\n \n
\n \n \nWu T. et al, (2021), Int J Obes (Lond)
\n \n \n \n\n \n
\n \n \n